177 related articles for article (PubMed ID: 31173544)
1. Changes of Serum IL-6, IL-17, and Complements in Systemic Lupus Erythematosus Patients.
Tang Y; Tao H; Gong Y; Chen F; Li C; Yang X
J Interferon Cytokine Res; 2019 Jul; 39(7):410-415. PubMed ID: 31173544
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum interleukin-34 level in juvenile systemic lupus erythematosus and disease activity.
El-Banna HS; El Khouly RM; Gado SE
Clin Rheumatol; 2020 May; 39(5):1627-1632. PubMed ID: 31907692
[TBL] [Abstract][Full Text] [Related]
3. Increased IL-23R
Izati AF; Mohd Shukri ND; Wan Ghazali WS; Che Hussin CM; Wong KK
Front Immunol; 2021; 12():690908. PubMed ID: 34484186
[TBL] [Abstract][Full Text] [Related]
4. Do high sensitivity C-reactive protein and serum interleukin-6 levels correlate with disease activity in systemic lupus erythematosuspatients?
Umare V; Nadkarni A; Nadkar M; Rajadhyksha A; Khadilkar P; Ghosh K; Pradhan VD
J Postgrad Med; 2017; 63(2):92-95. PubMed ID: 27531690
[TBL] [Abstract][Full Text] [Related]
5. Clinical associations of serum interleukin-17 in systemic lupus erythematosus.
Vincent FB; Northcott M; Hoi A; Mackay F; Morand EF
Arthritis Res Ther; 2013 Aug; 15(4):R97. PubMed ID: 23968496
[TBL] [Abstract][Full Text] [Related]
6. The model of circulating immune complexes and interleukin-6 improves the prediction of disease activity in systemic lupus erythematosus.
Thanadetsuntorn C; Ngamjanyaporn P; Setthaudom C; Hodge K; Saengpiya N; Pisitkun P
Sci Rep; 2018 Feb; 8(1):2620. PubMed ID: 29422675
[TBL] [Abstract][Full Text] [Related]
7. Serum and urine interleukin-17A levels as biomarkers of disease activity in systemic lupus erythematosus.
Nordin F; Shaharir SS; Abdul Wahab A; Mustafar R; Abdul Gafor AH; Mohamed Said MS; Rajalingham S; Shah SA
Int J Rheum Dis; 2019 Aug; 22(8):1419-1426. PubMed ID: 31179646
[TBL] [Abstract][Full Text] [Related]
8. C-reactive protein and complement components but not other acute-phase reactants discriminate between clinical subsets and organ damage in systemic lupus erythematosus.
Amezcua-Guerra LM; Springall R; Arrieta-Alvarado AA; Rodríguez V; Rivera-Martinez E; Castillo-Martinez D; Bojalil R
Clin Lab; 2011; 57(7-8):607-13. PubMed ID: 21888025
[TBL] [Abstract][Full Text] [Related]
9. Performance of cytokine models in predicting SLE activity.
Ruchakorn N; Ngamjanyaporn P; Suangtamai T; Kafaksom T; Polpanumas C; Petpisit V; Pisitkun T; Pisitkun P
Arthritis Res Ther; 2019 Dec; 21(1):287. PubMed ID: 31842967
[TBL] [Abstract][Full Text] [Related]
10. Aberrant expression of regulatory cytokine IL-35 in patients with systemic lupus erythematosus.
Cai Z; Wong CK; Kam NW; Dong J; Jiao D; Chu M; Lam CW; Tam LS
Lupus; 2015 Oct; 24(12):1257-66. PubMed ID: 25966926
[TBL] [Abstract][Full Text] [Related]
11. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus.
Chun HY; Chung JW; Kim HA; Yun JM; Jeon JY; Ye YM; Kim SH; Park HS; Suh CH
J Clin Immunol; 2007 Sep; 27(5):461-6. PubMed ID: 17587156
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Serum Interleukin (IL)-1β and IL-18 in Systemic Lupus Erythematosus.
Mende R; Vincent FB; Kandane-Rathnayake R; Koelmeyer R; Lin E; Chang J; Hoi AY; Morand EF; Harris J; Lang T
Front Immunol; 2018; 9():1250. PubMed ID: 29930551
[TBL] [Abstract][Full Text] [Related]
13. Elevated interleukin-18 levels correlated with disease activity in systemic lupus erythematosus.
Park MC; Park YB; Lee SK
Clin Rheumatol; 2004 Jun; 23(3):225-9. PubMed ID: 15168150
[TBL] [Abstract][Full Text] [Related]
14. Cytokines, 25-OH vit D and disease activity in patients with juvenile-onset systemic lupus erythematosus.
Abo-Shanab AM; Kholoussi S; Kandil R; Dorgham D
Lupus; 2021 Mar; 30(3):459-464. PubMed ID: 33183127
[TBL] [Abstract][Full Text] [Related]
15. Interleukin 1, interleukin 6, interleukin 10, and tumor necrosis factor α in active and quiescent systemic lupus erythematosus.
Cigni A; Pileri PV; Faedda R; Gallo P; Sini A; Satta AE; Marras R; Carta E; Argiolas D; Rum I; Masala A
J Investig Med; 2014 Jun; 62(5):825-9. PubMed ID: 24987977
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-32γ: Possible association with the activity and development of nephritis in patients with systemic lupus erythematosus.
Kwon OC; Ghang B; Lee EJ; Hong S; Lee CK; Yoo B; Kim S; Kim YG
Int J Rheum Dis; 2019 Jul; 22(7):1305-1311. PubMed ID: 30941928
[TBL] [Abstract][Full Text] [Related]
17. Serum ferritin as a serologic marker of activity in systemic lupus erythematosus.
Lim MK; Lee CK; Ju YS; Cho YS; Lee MS; Yoo B; Moon HB
Rheumatol Int; 2001 Apr; 20(3):89-93. PubMed ID: 11354563
[TBL] [Abstract][Full Text] [Related]
18. Elevated serum interleukin-15 levels in systemic lupus erythematosus.
Park YB; Kim DS; Lee WK; Suh CH; Lee SK
Yonsei Med J; 1999 Aug; 40(4):343-8. PubMed ID: 10487137
[TBL] [Abstract][Full Text] [Related]
19. The role of serum IL-17 and IL-6 as biomarkers of disease activity and predictors of remission in patients with lupus nephritis.
Abdel Galil SM; Ezzeldin N; El-Boshy ME
Cytokine; 2015 Dec; 76(2):280-287. PubMed ID: 26073684
[TBL] [Abstract][Full Text] [Related]
20. Cytokine production, serum levels and disease activity in systemic lupus erythematosus.
Gröndal G; Gunnarsson I; Rönnelid J; Rogberg S; Klareskog L; Lundberg I
Clin Exp Rheumatol; 2000; 18(5):565-70. PubMed ID: 11072595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
